Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Oruka Therapeutics (ORKA – Research Report), retaining the price target of $45.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mitchell Kapoor has given his Buy rating due to a combination of factors surrounding Oruka Therapeutics’ strategic moves and promising product development. The recent license agreement with Paragon to develop and commercialize IL-17A/F antibodies and products is a significant step for Oruka. This agreement places Oruka in a strong position to explore the potential of ORKA-002, an advanced IL-17A/F inhibitor with an extended half-life, which is designed to minimize dosing frequency while maintaining high efficacy.
The IL-17A/F inhibitors market is expected to evolve, replacing older IL-17A-only inhibitors that, despite achieving significant sales, offer only partial efficacy. The success of other IL-17A/F inhibitors like UCB’s Bimzelx, which recently received FDA approval, highlights the potential market opportunity for ORKA-002. Oruka’s plans for first-in-human dosing by the third quarter of 2025 and preliminary pharmacokinetic data by the first half of 2026 indicate a significant upcoming milestone that could validate the drug’s less frequent dosing advantage. These strategic developments and market dynamics underpin Kapoor’s confident Buy rating for Oruka Therapeutics.
In another report released on February 3, Wolfe Research also initiated coverage with a Buy rating on the stock with a $20.00 price target.